# EDGAR Filing Document

**Accession Number:** 0001800282
**File Stem:** 0001999371-25-008867
**Filing Date:** 2025-7
**Character Count:** 24003
**Document Hash:** b4c30e171f54cddfb5d30d3532974339
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001999371-25-008867.hdr.sgml**: 20250709

**ACCESSION NUMBER**: 0001999371-25-008867

**CONFORMED SUBMISSION TYPE**: ABS-15G

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20250709

**ITEM INFORMATION**: Findings and Conclusions of the Third Party Due Diligence Provider Obtained by the Issuer

**FILED AS OF DATE**: 20250709

**DATE AS OF CHANGE**: 20250709

**ABS RULE**: RULE-15GA2

**REGISTERED ENTITY**: N

**ABS ASSET CLASS**: Other

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Libra Solutions Securitization Funding, LLC
- **CENTRAL INDEX KEY:** 0001800282

**ORGANIZATION NAME:**
- **EIN:** 844298362
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** ABS-15G
- **SEC ACT:** Dodd Frank Act
- **SEC FILE NUMBER:** 025-04932
- **FILM NUMBER:** 251113287

**BUSINESS ADDRESS:**
- **STREET 1:** 9525 BRYN MAWR AVENUE, SUITE 900
- **CITY:** ROSEMONT
- **STATE:** IL
- **ZIP:** 60018
- **BUSINESS PHONE:** 8777338140

**MAIL ADDRESS:**
- **STREET 1:** 9525 BRYN MAWR AVENUE, SUITE 900
- **CITY:** ROSEMONT
- **STATE:** IL
- **ZIP:** 60018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oasis Securitization Funding, LLC
- **DATE OF NAME CHANGE:** 20200116
**DEPOSITOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Libra Solutions Securitization Funding, LLC
- **CENTRAL INDEX KEY:** 0001800282

**ORGANIZATION NAME:**
- **EIN:** 844298362
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** ABS-15G
- **SEC ACT:** Dodd Frank Act

**BUSINESS ADDRESS:**
- **STREET 1:** 9525 BRYN MAWR AVENUE, SUITE 900
- **CITY:** ROSEMONT
- **STATE:** IL
- **ZIP:** 60018
- **BUSINESS PHONE:** 8777338140

**MAIL ADDRESS:**
- **STREET 1:** 9525 BRYN MAWR AVENUE, SUITE 900
- **CITY:** ROSEMONT
- **STATE:** IL
- **ZIP:** 60018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oasis Securitization Funding, LLC
- **DATE OF NAME CHANGE:** 20200116

OMB Number: 3235-0675

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549<br>** 

<br> **FORM ABS-15G<br>ASSET-BACKED SECURITIZER<br> REPORT PURSUANT TO SECTION 15G OF<br> THE SECURITIES EXCHANGE ACT OF 1934**

**<u>LIBRA SOLUTIONS SECURITIZATION FUNDING, LLC</u>**

Check the appropriate box to indicate the filing obligation to which this form is intended to satisfy:

☐ Rule 15Ga-1 under the Exchange Act (17 CFR 240.15Ga-1) for the reporting period______________ to _________________

Date of Report (Date of filing) __________________

Commission File Number of securitizer: __________________

Central Index Key Number of securitizer:__________________

Name and telephone number, including area code, of the person<br> to contact in connection with this filing.

Indicate by check mark whether the securitizer has no activity to report for the initial period pursuant to Rule 15Ga-1(c)(l) ☐

Indicate by check mark whether the securitizer has no activity to report for the quarterly period pursuant to Rule 15Ga-1(c)(2)(i) ☐

Indicate by check mark whether the securitizer has no activity to report for the annual period pursuant to Rule 15Ga-1(c)(2)(ii) ☐

☒ Rule 15Ga-2 under the Exchange Act (17 CFR 240.15Ga-2)

Central Index Key Number of depositor: <u>0001800282</u>

 <u>LIBRA SOLUTIONS 2025-1 LLC</u> <br> (Exact name of issuing entity as specified in its charter)

Central Index Key Number of issuing entity (if applicable): <u>Not applicable</u>

Central Index Key Number of underwriter (if applicable): <u>Not applicable</u>

Shiven Shah, (646) 732-5900

Name and telephone number, including area code, of the person<br> to contact in connection with this filing.

**FINDINGS AND CONCLUSIONS OF THIRD-PARTY DUE DILIGENCE REPORTS**

**Item 2.01 Findings and Conclusions of a Third Party Due Diligence Report Obtained by the Issuing Entity**

The disclosures required by Rule 15Ga-2 (17 CFR 240.15Ga-2) are attached as Exhibit 99.1 to this Form ABS-15G. Please see the Exhibit Index for the related information.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the reporting entity has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | LIBRA SOLUTIONS SECURITIZATION FUNDING, LLC | LIBRA SOLUTIONS SECURITIZATION FUNDING, LLC |
| Date: July 9, 2025 | By: | /s/ Shiven Shah |
|  | Name: | Shiven Shah |
|  | Title: | Chief Financial Officer |

---

**EXHIBIT INDEX**

<u>Exhibit Number</u>

[99.1](ex99-1.htm) Independent Accountant's Report on Applying Agreed-Upon Procedures, dated July 8, 2025.

## Exhibit 99.1

[LIBRA SOLUTIONS 2025-1 LLC ABS-15G](libra-abs15g.htm)

**Exhibit 99.1**

![](ex99_002.jpg)

![](ex99_001.jpg)

**REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS** 

Board of Directors and Management of Libra Solutions Intermediate Holdco, LLC, Libra 2025-1 LLC, Triumph Capital Markets and Academy Securities, Inc.:

Grant Thornton LLP ("Grant Thornton", or "we") has performed the procedures enumerated below, on certain information with respect to attributes of Libra Solutions Intermediate Holdco, LLC's (the "Company") plaintiff and medical lien receivables as of May 31, 2025 (the "Subject Matter") related to Libra 2025-1 LLC's (the "Issuer") issuance of certain classes of Notes (the "Securitization Transaction"). The Company's management is responsible for the Data Files (as defined herein) accurately representing the information included in the underlying asset documents and the disclosed assumptions and methodologies.

The Company has agreed to and acknowledged that the procedures performed are appropriate to meet the intended purpose of assisting specified parties in evaluating the Subject Matter. This report may not be suitable for any other purpose. Additionally, the Issuer, Triumph Capital Markets ("Triumph") and Academy Securities, Inc. ("Academy" and together with the Company, Issuer and Triumph, the "Specified Parties") have agreed to and acknowledged that the procedures performed are appropriate for their purposes. The procedures performed may not address all the items of interest to a user of this report and may not meet the needs of all users of this report and, as such, users are responsible for determining whether the procedures performed are appropriate for their purposes.

Consequently, we make no representation regarding the appropriateness of the procedures enumerated below either for the purpose for which this report has been requested or for any other purpose.

The procedures performed on the plaintiff and medical lien receivables and associated findings are as detailed in Sections A and B herein. At the Company's instruction, for the purposes of our procedures, (i) differences of less or equal to $50, as applicable, were deemed to be in agreement, (ii) different forms of the same first name (for example Deb vs. Debbie vs. Deborah) were deemed to be in agreement (iii) differences due to punctuation were deemed to be in agreement and (iv) for the following date related Characteristics, differences of less than or equal to:

- 5 business days for the Funding Date Characteristic

- 30 days for the Payment Date Characteristics

- 90 days for the Invoice Date Characteristic

were deemed to be in agreement. Unless otherwise indicated, the following are defined for the purposes of our procedures:

· the phrase "compared" means we checked the information for agreement between sources, with any findings being reported unless
a deviation tolerance is otherwise noted. If applicable, such compared amounts and percentages are deemed to be in agreement if differences
were attributable to rounding.

![](ex99_003.jpg)

![](ex99_002.jpg)

· the phrase "recomputed" means, if applicable, we recalculated the number through mathematical calculation using the applicable
information in the Data Files as the inputs, with any findings being reported unless a deviation tolerance is otherwise noted. If applicable,
such recomputed amounts and percentages are deemed to be in agreement if differences were attributable to rounding.

the phrase "Source Documents" means a record containing details of a particular transaction or characteristic. Source Documents include the Contract, Lien, Attorney Letter, Letter of Protection, Funding Application, Payable Check Voucher, ACH Screenshot or Invoice ("Payment Support"), Checks, Bank Statements, Name Support Tables ("Name Support"), Facility Tables, Facility Agreements and screenshots from the Company's internal accounting systems ("System Application").

Due diligence agreed-upon procedures

**A.** **Data Files Agreed Upon Procedures** 

On June 13, 2025, the Company provided us with computer readable data files (the "Initial Data Files") containing certain characteristics of the plaintiff and medical lien receivables (the "Plaintiff and Medical Lien Receivables") included in the Securitization Transaction. The Plaintiff and Medical Lien Receivables are contained in three separate data pools, (i) the 2023-A pool ("23-A"), (ii) the New Production pool ("New Production") and (iii) the Trio Solution pool ("Trio" and together with 23-A and New Production, the "Collateral Pools"). The Company provided us with periodic updates received up to and including June 27, 2025 (together with the Initial Data Files, the "Data Files"). We performed the procedures indicated below on the Plaintiff and Medical Lien Receivables.

As instructed by the Company, Grant Thornton selected, on a random basis, 100 receivables, (the "Sample Assets") consisting of sixty-four (64) plaintiff receivables ("Plaintiff" or "Presettlement") and thirty-six (36) medical lien receivables ("Medical" or "Non-Presettlement"). The Plaintiff selections were comprised of:

· Twenty-two (22) plaintiff receivables from the "Libra PS Collateral Pool - 2023-A AR (5.31.2025) v2.xlsb" Data File,

· Twenty-one (21) plaintiff receivables from the "Libra PS Collateral Pool - New Production AR (5.31.2025).xlsb" Data File
and;

· Twenty-one (21) plaintiff receivables from the "Trio PS Collateral Pool (5.31.2025).xlsb" Data File to total.

The Medical selections were comprised of:

· Twelve (12) medical lien receivables from the "Libra ML Collateral Pool - 2023-A AR (5.31.2025) v2.xlsb" Data File,

· Twelve (12) medical lien receivables from the "Libra ML Collateral Pool - New Production AR (5.31.2025).xlsb" Data File
and

· Twelve (12) medical lien receivables from the "Trio ML Collateral Pool (5.31.2025).xlsb" Data File to

For each of the Sample Assets listed on Appendix A, we performed comparisons for certain characteristics (as identified in Exhibit 1) to certain available source documents (the "Source Documents").

![](ex99_002.jpg)

**Exhibit 1**

**Characteristics:**

---

| | | | |
|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Characteristic** | &nbsp;&nbsp;**Source Document** | &nbsp;&nbsp;**Type** |
| &nbsp;&nbsp;1 | &nbsp;&nbsp;Case Number | &nbsp;&nbsp;Contract, System Applications, Payment Support | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;2 | &nbsp;&nbsp;Funding Date | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;3 | &nbsp;&nbsp;Plantiff Last – First Name | &nbsp;&nbsp;Contract, System Application, Funding Application | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;4 | &nbsp;&nbsp;Funding Amount | &nbsp;&nbsp;Contract, System Application, Payment Support | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;5 | &nbsp;&nbsp;Principal Balance Outstanding | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;6 | &nbsp;&nbsp;Last Payment Date | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;7 | &nbsp;&nbsp;Receivable Type/PBM Bucket | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;8 | &nbsp;&nbsp;Funding Receipts | &nbsp;&nbsp;Contract, System Application, Payment Support | &nbsp;&nbsp;Plaintiff |
| &nbsp;&nbsp;9 | &nbsp;&nbsp;Vendor/Facility | &nbsp;&nbsp;Contract, System Application, Payment Support, Facility Table, Facility Agreements | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;10 | &nbsp;&nbsp;Patient ID | &nbsp;&nbsp;Contract, System Application, Payment Support, | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;11 | &nbsp;&nbsp;UPV (Site Cost) | &nbsp;&nbsp;Contract, System Application, Payment Support | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;12 | &nbsp;&nbsp;Invoice Date | &nbsp;&nbsp;Contract, System Application, Payment Support | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;13 | &nbsp;&nbsp;Payment Date Received | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;14 | &nbsp;&nbsp;Principal Balance Outstanding/Balance | &nbsp;&nbsp;Contract, System Application | &nbsp;&nbsp;Medical |
| &nbsp;&nbsp;15 | &nbsp;&nbsp;Proof of Funding | &nbsp;&nbsp;Contract, System Application, Payment Support | &nbsp;&nbsp;Medical |

---

For Characteristic 1, the Company instructed Grant Thornton that this characteristic is not applicable for the Trio pool.

For Characteristic 3, we were instructed by the Company to compare only the first and last name and to disregard any middle initial, middle name or suffix.

![](ex99_002.jpg)

For Characteristic 5, we were instructed by the Company to use the "Due" balance from the Source Documents as the Grant Thornton value it there is no payment balance. If there is a payment balance and the payment was made subsequent to May 31, 2025, the value will be the sum of the principal balance and DPF amount from the source document.

For Characteristic 6, we were instructed by the Company that, if the Funding amount is equal to the Principal Balance Outstanding, the value is "0" or "1/0/1900".

For Characteristic 9, we were instructed by the Company that the name of the Vendor can be supported by either the Payee or Vendor name on the Payable Check Voucher or ACH Screenshot.

We noted no discrepancies in connection with the characteristics listed in Exhibit 1 between the Data Files and the Source Documents.

**B.** **Documentation Agreed Upon Procedures** 

For each of the Plaintiff Sample Assets, Grant Thornton observed the existence of the following documentation, or compared and agreed information contained within the following documentation (as described below):

- Inspected the existence of a Funding Application; The Company has instructed us that this is not applicable to Trio receivable selections.

- Inspected the existence of a Signed Contract.

- Both the customer and Attorney signed the contract, or if the Attorney has not signed the contract, the presence of an Attorney Letter.

Compared and agreed the Name on the Funding Application to the Signed Contract. The Company has instructed us that this is not applicable for the Trio receivable selections. For those 23-A and New Production receivables, Sample Assets where the Name on the Funding Application does not match the name on the Signed Contract, we were instructed by the Company to use the Name Support provided by the Company to compare against the Signed Contract.

For each of the Medical Lien Sample Assets, Grant Thornton observed the existence of the following documentation, or compared and agreed information contained within the following documentation (as described below):

- Inspected the signed Contract for signatures from the Company and vendor.

- Compared and agreed the Patient ID to the related invoice / Check Payable Voucher/ACH Screenshot.

- Compared and agreed the name of the medical facility (vendor) to the signed Contract.

- Inspected the presence of a signed lien.

- For those Medical Sample Assets without a lien, inspected that a Letter of Protection ("LOP") was obtained.

We noted no discrepancies in documentation.

![](ex99_002.jpg)

We were engaged by the Company to perform this agreed-upon procedures engagement and conducted our engagement in accordance with attestation standards established by the American Institute of Certified Public Accountants. We were not engaged to and did not conduct an examination or review, the objective of which would be the expression of an opinion or conclusion, respectively, on the Subject Matter. Accordingly, we do not express such an opinion or conclusion. Had we performed additional procedures, other matters might have come to our attention that would have been reported to you.

Our agreed-upon procedures engagement was not conducted for the purpose of the following:

· Addressing the conformity of the origination of the assets to stated underwriting or credit extension guidelines, standards, criteria,
or other requirements;

· Addressing the value of collateral securing any such assets being securitized;

· Addressing the compliance of the originator of the assets with federal, state, and local laws and regulations;

· Satisfying any criteria for due diligence published by a nationally recognized statistical rating organization ("NRSRO");

· Addressing any other factor or characteristic of the assets that would be material to the likelihood that the issuer of the asset-backed
security will pay interest and principal in accordance with applicable terms and conditions, including but not limited to whether the
characteristics have implications on the future performance of the assets, underwritten value of the assets, credit quality of the assets,
likelihood of return to investors or any other implications related to the assets or the related asset-backed securities;

· Forming any conclusions; and

· Any other terms or requirements of the transaction that do not appear in this report.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements related to our agreed-upon procedures engagement.

This report is intended solely for the information and use of the Specified Parties. It is not intended to be, and should not be, used by anyone other than these specified parties, including investors and rating agencies, who are not identified as specified parties but who may have access to this report as required by law or regulation.

/s/ GRANT THORNTON LLP

Chicago, Illinois<br> July 8, 2025

![](ex99_002.jpg)

**APPENDIX A**

![](ex99_002.jpg)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Presettlement Sample Assets | &nbsp;&nbsp;Presettlement Sample Assets | &nbsp;&nbsp;Presettlement Sample Assets | &nbsp;&nbsp;Presettlement Sample Assets | &nbsp;&nbsp;Presettlement Sample Assets | &nbsp;&nbsp;Presettlement Sample Assets |
| &nbsp;&nbsp;<br> Libra 2023-A Pool | &nbsp;&nbsp;<br> Libra 2023-A Pool | &nbsp;&nbsp;New Production Pool | &nbsp;&nbsp;New Production Pool | &nbsp;&nbsp;Trio Pool | &nbsp;&nbsp;Trio Pool |
| &nbsp;&nbsp;Selection # | &nbsp;&nbsp;Plantiff Sample Asset Identifier | &nbsp;&nbsp;Selection # | &nbsp;&nbsp;Plantiff Sample Asset Identifier | &nbsp;&nbsp;Selection # | &nbsp;&nbsp;Plantiff Sample Asset Identifier |
| &nbsp;&nbsp;1 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;23 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;44 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;2 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;24 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;45 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;3 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;25 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;46 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;4 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;26 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;47 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;5 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;27 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;48 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;6 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;28 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;49 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;7 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;29 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;50 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;8 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;30 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;51 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;9 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;31 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;52 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;10 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;32 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;53 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;11 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;33 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;54 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;12 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;34 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;55 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;13 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;35 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;56 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;14 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;36 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;57 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;15 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;37 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;58 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;16 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;38 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;59 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;17 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;39 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;60 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;18 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;40 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;61 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;19 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;41 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;62 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;20 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;42 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;63 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;21 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;43 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;64 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;22 | &nbsp;&nbsp;[Redacted] |  |  |  |  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;Medical Lien Sample Assets | &nbsp;&nbsp;Medical Lien Sample Assets | &nbsp;&nbsp;Medical Lien Sample Assets | &nbsp;&nbsp;Medical Lien Sample Assets | &nbsp;&nbsp;Medical Lien Sample Assets | &nbsp;&nbsp;Medical Lien Sample Assets |
| &nbsp;&nbsp;<br> Libra 2023-A Pool | &nbsp;&nbsp;<br> Libra 2023-A Pool | &nbsp;&nbsp;New Production Pool | &nbsp;&nbsp;New Production Pool | &nbsp;&nbsp;Trio Pool | &nbsp;&nbsp;Trio Pool |
| &nbsp;&nbsp;Selection # | &nbsp;&nbsp;Medical Lien Asset Identifier | &nbsp;&nbsp;Selection # | &nbsp;&nbsp;Medical Lien Asset Identifier | &nbsp;&nbsp;Selection # | &nbsp;&nbsp;Medical Lien Asset Identifier |
| &nbsp;&nbsp;1 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;13 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;25 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;2 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;14 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;26 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;3 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;15 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;27 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;4 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;16 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;28 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;5 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;17 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;29 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;6 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;18 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;30 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;7 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;19 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;31 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;8 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;20 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;32 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;9 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;21 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;33 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;10 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;22 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;34 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;11 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;23 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;35 | &nbsp;&nbsp;[Redacted] |
| &nbsp;&nbsp;12 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;24 | &nbsp;&nbsp;[Redacted] | &nbsp;&nbsp;36 | &nbsp;&nbsp;[Redacted] |

---